| Peter George Casten Jr, MD MPH | |
|
701 University Blvd East, Ste 211, Tuscaloosa, AL 35401 | |
| (205) 333-4300 | |
| (205) 343-8150 |
| Full Name | Peter George Casten Jr |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 701 University Blvd East, Tuscaloosa, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558412122 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Peter George Casten Jr, MD MPH 701 University Blvd East, Ste 211, Tuscaloosa, AL 35401 Ph: (205) 333-4300 | Peter George Casten Jr, MD MPH 701 University Blvd East, Ste 211, Tuscaloosa, AL 35401 Ph: (205) 333-4300 |
News Archive
Boston University researchers, in collaboration with Centers for Therapeutic Innovation at Pfizer Inc., have discovered a novel molecular pathway needed to regulate kidney podocytes-special octopus-like cells that are critical in maintaining normal kidney function.
The regulation, five years in the making, means insurers won't be able to charge higher co-payments or deductibles for mental health services than they charge for treating physical ailments. Here's a sampling of this afternoon's news coverage of the final rule.
Senate Majority Leader Harry Reid said on Tuesday "he will attempt to pass a 'clean' one-month stopgap funding measure at current spending levels when the Senate returns next week, in a bid to avoid a government shutdown," CQ reports.
Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.
Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015.
› Verified 6 days ago